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Multiresistant pathogens: The case of 
non-fermentative Gram-negative bacilli 
[ E l  Changes in classification of 
glucose-non-fermenting gram-negative bacilli 
A. Bauernfeind. Max von Pettenkofer-Institut, Munchen, Germany 
Modern taxonomy is polyphasic and incorporates genotypic, pheno- 
typic and phylogenetic markers. Genotypic characteristics are based 
on analysis of DNA or RNA molecules. rRNA is currently regarded 
as the optimal target for phylogenetic analysis as it is composed of 
lughly conserved as well as variable domains. At this time direct 
DNA-sequencing of coding regions for 16s or 23s rRNA is widely 
performed. Phenotypic procedures include all non-nucleic acid &- 
rected approaches, e.g. composition of cell wall or cellular fatty acids, 
whole cell protein analysis etc. 
Recent progress in technology allowed accumulation of new data 
leadmg to revisions in taxonomy and nomenclature (Bruckner & 
Colonna, CID, 1995) in major groups of bacteria. This holds true 
as well for glucose-non-fermenting gram-negative bacilli, e.g. Acine- 
tobacter, Pseudomom and others. Major reclassifications concern the 
genus Pseudomonac. It was subdivided into five rRNA-DNA-homol- 
ogy groups by Palleroni et al. in 1973. The genus Pseudomonac is now 
restricted to the former rRNA-group I, the species of rWA-group 
11 were transferred to the new genera Burkholdm'a and Ralrtonia, 
rRNA-group I11 became the family Comamonaduceae, rRNA-group 
IV was transferred to the genus Brevundimonas, and rWA-group V to 
Stenorrophomonac (via Xanthomonas) . 
Recently molecular procedures based on specific signature se- 
quences within the 16s or 23s rRNA have been designed to iden- 
nfy species, e.g. within the genus Burkholdm'a. They improve iden- 
dfication of species &cult to separate by phenotypic procedures. 
There are, however, examples which demonstrate the limitations of 
genetic procedures, e.g. to Merentiate between the phenotypically 
&tinct species Burkholderia cepm.a and B. vietnamiensis. T h  under- 
lines the importance of polyphasic taxonomy for A d  dassification 
and nomenclature. 
I S216 I Cross-Infection with Multiresistant 
Pseudomonas, Burkholderia and Other 
Non-Fetmenters in Cystic Fibrosis Patients 
N. H0iby. Dept. Clin. Minobiof., Rigshospitafet, Copenhagen, Denmark 
The major Gram-negative pathogens responsible for respiratory in- 
fection and mortality in cystic fibrosis (CF) are Pseudomonas amg- 
inosa and Burkholdm'a cepm'a. However, Stenohophomonas maltophilia 
and Alcaligenes xylosoxidans and a few other non-fermenting species 
are emerging as possibly important patogens due to the improved 
survial of the patients. All these species are increasingly resistant to 
most of the available antibiotics which are used extensively in CF 
patients. Difficult-to-treat strains and multiply resistant st ra ins  are 
therefore becoming an increasing problem in CF centres. Unform- 
nately, cross-infection has been documented with at least I! aeruginosa 
and B. cepacia in CF centres, in the wards, in the out-patient clinics, 
in summer-camps and during social activities such as fitness-classes. 
Even spread of epidemic s t r a i n s  between centres and between coun- 
tries and between continents has been observed. Such transmissible 
s t r a i n s  are often multiply resistant due to the selective pressure im- 
posed by the exttensive use of antibiotics in CF patients. The most 
effective preventive measure has been the use of cohorte isolation 
technique and high level of hygine in CF centres and during social 
activities. The cohorting is based on bacteriological examination of 
sputum, and e.g. patients culture-positive for I! amginosa are kept 
isolated by geography and/or time &om culture-negative patients. 
Social activities such as summer camps are completely avoided in 
some counmes. 
Acinetobacter: facts and fears 
ED. Daschner. Instihrteefor Environmental Medicine and Hospital 
Epidemiology, University Hospital, Freibug, Germany 
The presentation will cover the following fkcts: Epidemiologi- 
cal sigruficance of cutaneous, pharyngeal and digestive tract colonisa- 
tion by Acinetobucter, sunrival ofticinetobucter on dry surfaces, nosoco- 
mid outbreaks, risk factors for nosocomial colonisation, laboratory 
investigations of outbreaks, antimicrobial susceptibhlty. 
Fears: Why are hospital epidemiologists very much a.6aid of 
Acinetobucter? Why is it difficult to get rid of these organisms in hos- 
pitals when they colonise patients especially in intensive care units? 
Is there airborne spread of Acinetobacter? 
1 S218 I Moraxella and Oligella: Ecology and 
A. von Graevenitz. C H  
No abstract available. 
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I S2191 Retroviruses for Gene Delivery 
Y. Takeuchi, E Martin Molina, K. Palmer, M. Collins. Chester 
Beatty Laboratories, London, UK 
We have demonstrated that the sensitivity of retroviruses to human 
serum is controlled by the expression or alpha 1-3 galactosyl sugar 
epitopes. We have now made hgh titre packaging cells producing 
viruses resistant to human serum. We are also attempting to retar- 
get retroviruses to novel surface receptors using an insertion point 
in the MLV envelope which allows incorporation of an additional 
receptor binding domain. Our results with chimeric envelopes ex- 
pressing ligands or single chain antibodies will be &cussed. Finally, 
our strategies using retroviruses for tumour gene therapy will be 
presented. These include ex vivo modification of -our c& which 
are being used in a melanoma vaccine clinical trial and targetting 
retroviral delivery to tumour cells. 
[s2201 Genetic Approaches for HIV Infection: Promises 
D. Trono. Salk Institutefor Biological Studies, Sun diego, C A ,  USA 
First developed for heremtary &orders, gene therapy is also envi- 
sioned for the treatment of oncologic and infectious diesases. In the 
latter case, the genetic modification of cells is aimed at reducing or 
ablating the replication of a pathogen, resulting in what has been 
called an "intracellular immunization". In spite of the recent success 
of pharmaceutical approaches for the management of HIV-induced 
disease, currently available antiviral drugs are toxic, costly, and need 
to be administered for an extremely long time, if not for the pa- 
tients' entire life. Based on t h i s  premise, genetic approaches might 
represent a valid if only complementary approach for the mtment  
ofHIV mfection. The progress made towards meeting thu; objective, 
as well as the problems snll remaining and their potential solutions, 
d be discussed. 
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I S221 I Gene Therapy for Cystic Fibrosis: Where Do We 
E.W.EW Alton. Ion Transport Unit, National Heart G Lung Institute, 
London, United Kingdom 
The cystic fibrosis (CF) gene was cloned was in 1989, and the feasi- 
bility of in vitro gene theram demonstrated by 1991. With the devel- 
opment of CF mouse models, two groups demonstrated that CFTR 
gene transfer is able to correct, at least in part, the bioelectrical ab- 
normality characteristic of CE As a result of these and other studies, 
CF gene therapy has moved into the clinical arena. Currently, 4 &- 
ical trials have been reported with at least another dozen underway 
or recently completed. The preliminary data available from these 
studies suggests that both adenowal and cationic liposome medlated 
gene transfer can be demonstrated at the level of both mRNA and 
protein. With respect to functional correction, approximately 30% 
of subjects studied have demonstrated evidence of some degree of 
correction of the chloride abnormality characteristic of CE A num- 
ber of safety issues have arisen with regard to adenoviral mediated 
gene transfer, whilst to date liposomes have proved to be safe. The 
data from these studies will be reviewed in this presentation. 
Stand 
El Congenital Immuno-Deficiency 
C. Bordignon. I 
No abstract available. 
Latest lessons from experimental models 
(ESCMID European Network for the Study of 
Experimental Infections) 
Molecular Mediators of Brain Injury in 
Experimental Meningitis 
M.G. Tauber. CH 
No abstract available. 
I S224 I Latest Lessons from Experimental Models 
M.G. Bergeron. Lavaf University, Quibec city, Canada 
Objectives: Anunal models have been traditionally used to evaluate 
the pathogenesis of infectious diseases or to investigate the safety, 
pharmacokmetics, pharmacodynamics and/or efficacy of antimicro- 
bials. From these models, parameters of antibiotic use have evolved 
and have helped in the management of specific diseases like menin- 
gitis or endocarditis. Recently some antibiotics have been shown 
to modulate host response. Appropriately designed, experimental 
models may become powerful tools to explore not only the in vivo 
antimicrobial activity of antibiotics but their Biological Response 
Modifiers (BRM) properties. 
Methods: A murine model of pneumococcal pneumonia was 
developed i) to study the chronology of events which mediates the 
progression of the inflammatory response and leads to death, ii) to 
detect specific markers of disease progression, and iii) to evaluate 
how antibiotics can interact with the immune system and control 
this deadly infection. 
Results: There was no correlation between the kinetics of cy- 
tokines in blood and that observed in bronchoalveolar fluid PAL) 
or lung. The simultaneous elevation of IL-6 and TNF observed in 
blood may be a sign of poor prognosis and imminent death, whde 
high level of IL-6 may suggest early disease mth  limited lung dam- 
age. In this model, cefodizime (Cet) dld reduce the level of LTB4 
and neutrophil recruitments in the lungs of infected animals. More- 
over, this B-lactam dld selectively inhibit TNF and IL-6 in BAL and 
lung tissue without altering IL-1 production. By reducing the over- 
w h e h n g  dammatory response that occurs during severe pneu- 
monia, thrs antibiotic may protect the host in unique ways. 
Conclusions: Animal studies based at developing strateges of 
immune modulation may eventually lead to therapies of unparalleled 
efficacy and safety. 
182251 Understanding Host Defence Mechanisms by 
J.Y. Cesbron. F 
No abstract available. 
Gene Manipulation 
I S226 I Pneumonia: News from the Experimental 
Models 
WR. Wdson. USA 
No abstract available. 
Evolving natural history and prognostic 
factors in febrile neutropenia 
(ESCMID Working Party on Infections in 
Cancer Patients) 
[El Evolving Natural History and Prognostic Factors 
M. Paesmans, K. Rolston, E. Rubenstein, R. Feld, B. De Pauw, 
M.F! Glauser, A. Cometta, J. Klasteaky for the h4ASCC Infectious 
Committee. InstitutJufes Bordet, BmseL, Belgium 
Since December 1994, the Infectious Committee of the Multi- 
national Association for Supportive Care in Cancer (MASCC) is 
conducting a survey, in a multicenhic, multinational setting among 
febrile neumpenic cancer patients @ts) in order to idennfy features 
at presentation able to predict a good outcome or the occurrence of 
a serious medlcal complication with a particular interest in an ex- 
ternal validation of the prediction rule published by Talcott in JCO 
(1992) where pts are allocated into 4 groups: I: inpts, 11: outpts with 
comorbidity, 111: outpn with unconmlled cancer, M outpts with- 
out comorbidity or uncontrolled cancer. Up to January 31, 1997, 
about 900 eligible pts have been followed for one episode. Interim 
descriptive results currently available are the following: median age is 
52 yn with 49% of male pts. Underlying &ease was hematologic in 
46%, lymphoma/Hodgkinb disease in 20%. solid tumor in 26% and 
other in 9 %  23% did undergo a transplantation. A clinical site was 
found in 42% and TalcottS group distribution was: I:62%, II:13%, 
III:9% and IV16%. Initial empiric antibiotic treatment was success- 
ful in 55%, a serious medical complication occurred in 17% with 
a 7% death rate. Closure of the survey d occur soon, after 1000 
episodes and defimtive results including inferential analysis will be 
available at the meeting. 
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